Christopher Rowbottom

Christopher Rowbottom currently serves as a Scientific Director at Moderna, overseeing DMPK projects with a focus on coordinating and designing in vitro and in vivo PK/PD studies to support immuno-oncology initiatives within the mRNA modality. Previous experience includes roles at Biogen as a Scientist I leading the transporter group for in-vitro preclinical and clinical DDI/regulatory studies, as well as a Principal Researcher at Eisai Inc where the development and evaluation of transporter assays were emphasized. Early in the career, Christopher held positions as a Research Chemist at ERI and in QC at Aventis. Academic credentials include completion of HMX Fundamentals in Immunology from Harvard Medical School and a Bachelor of Science in Biochemistry from Michigan State University.